Terms: = Gastric cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
2797 results:
1. gastric cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.
Shen J; Li M
Crit Rev Immunol; 2024; 44(5):1-13. PubMed ID: 38618724
[TBL] [Abstract] [Full Text] [Related]
2.
Kalisperati P; Spanou E; Pateras IS; Evangelou K; Thymara I; Korkolopoulou P; Kotsinas A; Vlachoyiannopoulos PG; Tzioufas AG; Kanellopoulos C; Gorgoulis VG; Sougioultzis S
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612698
[No Abstract] [Full Text] [Related]
3. [Pyloric gland adenoma - a rare tumor of the upper gastrointestinal tract with a high risk of malignancy].
Tertychnyy AS; Pachuashvili NV; Protsenko DD; Avraamova ST; Nagornaya DP; Pavlov PV; Kiryukhin AP; Fedorenko AA
Arkh Patol; 2024; 86(2):30-36. PubMed ID: 38591904
[TBL] [Abstract] [Full Text] [Related]
4. [High expression of COX6B2 in gastric cancer is associated with poor long-term prognosis and promotes cell proliferation and cell cycle progression by inhibiting p53 signaling].
Shen M; Zhao N; Deng X; Deng M
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):289-297. PubMed ID: 38501414
[TBL] [Abstract] [Full Text] [Related]
5. Valproate modulates the activity of multidrug resistance efflux pumps, as a chemoresistance factor in gastric cancer cells.
Hosseini SA; Mirzaei SA; Kermani S; Yaghoobi H
Mol Biol Rep; 2024 Mar; 51(1):427. PubMed ID: 38498238
[TBL] [Abstract] [Full Text] [Related]
6. Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.
Deng YY; Sun Y; Wu SJ; Zhang TY; Yang J; Liu K
J Cell Mol Med; 2024 Apr; 28(7):e18174. PubMed ID: 38494839
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Classifications in gastric cancer: A Call for Interdisciplinary Collaboration.
Díaz Del Arco C; Fernández Aceñero MJ; Ortega Medina L
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473896
[TBL] [Abstract] [Full Text] [Related]
8. RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation.
Suh YS; Lee J; George J; Seol D; Jeong K; Oh SY; Bang C; Jun Y; Kong SH; Lee HJ; Kim JI; Kim WH; Yang HK; Lee C
Br J Cancer; 2024 May; 130(9):1571-1584. PubMed ID: 38467827
[TBL] [Abstract] [Full Text] [Related]
9. A genome-wide study of gastric intramucosal neoplasia based on somatic copy number alterations, gene mutations, and mRNA expression patterns.
Koike Y; Osakabe M; Sugimoto R; Uesugi N; Matsumoto T; Suzuki H; Yanagawa N; Sugai T
J Pathol Clin Res; 2024 Mar; 10(2):e12368. PubMed ID: 38454538
[TBL] [Abstract] [Full Text] [Related]
10. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia.
Yang T; Gou H; Lin T; Yang Y; Jin X; Dong T; Zhang Y; Chen X
Int J Pharm; 2024 Apr; 654():123971. PubMed ID: 38452832
[TBL] [Abstract] [Full Text] [Related]
11. The role of mir96 in predicting CTC status and prognostic evaluation in gastric cancer patients.
Zheng Q; Ge H
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):264-274. PubMed ID: 38430012
[TBL] [Abstract] [Full Text] [Related]
12. cancer Risks Associated With
Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
[TBL] [Abstract] [Full Text] [Related]
13. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming.
Zou G; Huang Y; Zhang S; Ko KP; Kim B; Zhang J; Venkatesan V; Pizzi MP; Fan Y; Jun S; Niu N; Wang H; Song S; Ajani JA; Park JI
J Exp Med; 2024 Apr; 221(4):. PubMed ID: 38411616
[TBL] [Abstract] [Full Text] [Related]
14. Identification of ferroptosis-related subtypes, characteristics of TME infiltration and development of prognostic models in gastric cancer.
Tang X; Yu Y; Liu N; Su Y; Zhang K; Zhai Z; Chen C; Sun W; Chen D; Ling R
Int Immunopharmacol; 2024 Mar; 130():111610. PubMed ID: 38402832
[TBL] [Abstract] [Full Text] [Related]
15. Killer cell lectin-like receptor G2 facilitates aggressive phenotypes of gastric cancer cells via dual activation of the ERK1/2 and JAK/STAT pathways.
Ito Y; Kanda M; Sasahara M; Tanaka C; Shimizu D; Umeda S; Inokawa Y; Hattori N; Hayashi M; Nakayama G; Kodera Y
Gastric Cancer; 2024 May; 27(3):506-518. PubMed ID: 38386237
[TBL] [Abstract] [Full Text] [Related]
16. Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
17. Epigenetic disruption of histone deacetylase-2 accelerated apoptotic signaling and retarded malignancy in gastric cells.
Hosseini SA; Ghatrehsamani M; Yaghoobi H; Elahian F; Mirzaei SA
Epigenomics; 2024 Mar; 16(5):277-292. PubMed ID: 38356395
[TBL] [Abstract] [Full Text] [Related]
18. Recognizing the role of Epstein-Barr virus in gastric cancer: transcriptomic insights into malignancy modulation.
Anbouhi TS; Sazegar H; Rahimi E
Virol J; 2024 Feb; 21(1):41. PubMed ID: 38355581
[TBL] [Abstract] [Full Text] [Related]
19. Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in gastric cancer.
Morgos DT; Stefani C; Miricescu D; Greabu M; Stanciu S; Nica S; Stanescu-Spinu II; Balan DG; Balcangiu-Stroescu AE; Coculescu EC; Georgescu DE; Nica RI
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339127
[TBL] [Abstract] [Full Text] [Related]
20. Investigating
Teixeira E; Fernandes C; Bungărdean M; Paula ADC; Lima RT; Batista R; Vinagre J; Sobrinho-Simões M; Máximo V; Soares P
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338801
[TBL] [Abstract] [Full Text] [Related]
[Next]
